Focus on Patients
-
Drug Development Must Meet Complex, Diverse Needs Of The Opioid Use Disorder Community
8/7/2023
With almost 80,000 opioid overdose deaths in 2022, the surge in opioid-related overdoses and deaths in the United States has continued at a relentless pace. Treatments are available, but with more diverse therapies and flexible trial designs, more patients will be able to begin their journey to recovery.
-
Shared Knowledge & Shared Data Is Crucial To Developing Innovative Therapies For SCIs
7/7/2023
In this Q&A, Chief Science Officer Marco Baptista, Ph.D., discusses the Christopher & Dana Reeve Foundation's focus on and approach to data and knowledge sharing, as well as patient engagement, as it works to advocate for and fund the development of spinal cord injury (SCI) therapeutics.
-
Building Health Equity By Minimizing Barriers To Clinical Trial Participation
7/5/2023
The pharmaceutical industry continuously works to address the unmet needs of patients, including the need for therapies that work for as many people as possible. Yet, we continue to see a lack of diversity in clinical trials. Janssen's Lisa Lewis details how we can all come together to improve patient diversity and improve outcomes for all people.
-
Advancing Alzheimer’s Disease Treatment With An OLE, Expanded Access, & A Better Patient Experience
6/21/2023
TrueBinding CEO Dongxu Sun, Ph.D. discusses the journey toward an Alzheimer’s disease drug that reduces (and reverses) symptoms — supported by an open label extension (OLE), compassionate use designation, and careful attention to patient experience.
-
Patient-Powered AI Is Driving Science And Innovation Forward
5/17/2023
Drug discovery is a game of information: If we understand disease well, we know where to intervene and how to design a molecule to target the disease. AI can be used to integrate the patient experience and voice into solutions, further enhancing their relevance.
-
Advancing Innovative Therapies For Mild-To-Moderate Psoriasis With Novel PASI-HD Assessment
5/8/2023
The Psoriasis Area and Severity Index, or PASI, was developed in the 1970s as a tool for assessing the severity of psoriatic lesions for the purpose of assessing outcomes in a psoriasis clinical development program. But it falls short in assessing the severity of the disease in those wild mild to moderate psoriasis. Enter PASI-HD.
-
Patient-Centric Clinical Development For Rare Disease Treatments
4/28/2023
Incorporating patients into every step of the process is integral to overcoming obstacles related to clinical development of rare disease treatments. Obtaining early patient input, designing meaningful clinical trials, and considering manufacturing strategy early is crucial.
-
New Advancement Toward The First Primary Endpoint Qualification Of A Digital Endpoint For Duchenne
4/27/2023
Current methods for assessing ambulatory function in patients with Duchenne muscular dystrophy do not fully reflect how they experience DMD in their daily lives. Now, researchers have developed a new endpoint measured by a wearable device that records a patient's fastest spontaneous strides outside the clinic. What's more, it could become the first-ever digital primary endpoint approved by regulators.
-
More Focus And Funding Becomes Crucial To Curing Colorectal Cancer
4/12/2023
Advancements in the treatment of colorectal cancer have undoubtedly been made in recent years, but unfortunately, they are not enough to combat this deadly disease. Fight Colorectal Cancer President Anjee Davis addresses the critical lack of funding for colorectal cancer clinical trials and treatment options.
-
AI And Healthcare Disparities: Driving A Wedge Or Closing The Gap?
3/31/2023
The enthusiasm for the role of AI in upgrading global health and care provision is justified, provided we understand that the path to success is just as much about communication and collaborative development as it is about the raw potential of the technology itself. Because realizing this technological potential requires us to consider the role of people and processes in an integrated approach.